Antimetabolites
UCB Transplant After Non-Myeloablative Prep for Blood Cancers
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial is testing a new cancer treatment that uses a less intense form of chemotherapy followed by a bone marrow transplant. The new treatment is based on the patient's diagnosis, disease status, and prior treatment.
Anti-metabolites
Cord Blood Transplant for Leukemia
Recruiting3 awards4 criteria
Minneapolis, Minnesota
This trial is testing a new way to treat leukemia with an unrelated umbilical cord blood transplant. The transplant will use a myeloablative preparative regimen, which will include the drugs cyclophosphamide, fludarabine, and fractionated total body irradiation.
Popular Filters
Trials for Leukemia Patients
Monoclonal Antibodies
Isatuximab + Dexamethasone + Lenalidomide for Multiple Myeloma
Recruiting1 awardPhase 2
Salt Lake City, Utah
This trial aims to study a new approach for treating very frail patients with multiple myeloma. The researchers believe that starting treatment slowly and gently, with a combination of Isatuximab and d
Chemotherapy
Stem Cell Transplant + Chemo for Blood Cancer
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial involves preparing patients with drugs and radiation before giving them a donor stem cell transplant. After the transplant, medications are used to prevent rejection of the new cells. It targets patients who need stem cell transplants.
Procedure
Individualized Treatment Plans for Multiple Myeloma
Recruiting1 award14 criteria
Seattle, Washington
This trial is testing whether high-throughput drug sensitivity and genomics data can be used to develop individualized treatment plans for patients with multiple myeloma or plasma cell leukemia.
Hematopoietic Stem Cell Transplantation
HSCT for Leukemia and Lymphoma
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial is testing a new way to give an allogeneic HCT, which is a transplant of blood-forming cells from a donor. This new method uses a myeloablative preparative regimen, which is a way to kill cancer cells, followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen.
Trials for Prolymphocytic Leukemia Patients
Monoclonal Antibodies
Isatuximab + Dexamethasone + Lenalidomide for Multiple Myeloma
Recruiting1 awardPhase 2
Salt Lake City, Utah
This trial aims to study a new approach for treating very frail patients with multiple myeloma. The researchers believe that starting treatment slowly and gently, with a combination of Isatuximab and d
Chemotherapy
Stem Cell Transplant + Chemo for Blood Cancer
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial involves preparing patients with drugs and radiation before giving them a donor stem cell transplant. After the transplant, medications are used to prevent rejection of the new cells. It targets patients who need stem cell transplants.
Procedure
Individualized Treatment Plans for Multiple Myeloma
Recruiting1 award14 criteria
Seattle, Washington
This trial is testing whether high-throughput drug sensitivity and genomics data can be used to develop individualized treatment plans for patients with multiple myeloma or plasma cell leukemia.
Hematopoietic Stem Cell Transplantation
HSCT for Leukemia and Lymphoma
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial is testing a new way to give an allogeneic HCT, which is a transplant of blood-forming cells from a donor. This new method uses a myeloablative preparative regimen, which is a way to kill cancer cells, followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen.
Trials With No Placebo
Monoclonal Antibodies
Isatuximab + Dexamethasone + Lenalidomide for Multiple Myeloma
Recruiting1 awardPhase 2
Salt Lake City, Utah
This trial aims to study a new approach for treating very frail patients with multiple myeloma. The researchers believe that starting treatment slowly and gently, with a combination of Isatuximab and d
Chemotherapy
Stem Cell Transplant + Chemo for Blood Cancer
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial involves preparing patients with drugs and radiation before giving them a donor stem cell transplant. After the transplant, medications are used to prevent rejection of the new cells. It targets patients who need stem cell transplants.
Procedure
Individualized Treatment Plans for Multiple Myeloma
Recruiting1 award14 criteria
Seattle, Washington
This trial is testing whether high-throughput drug sensitivity and genomics data can be used to develop individualized treatment plans for patients with multiple myeloma or plasma cell leukemia.
Hematopoietic Stem Cell Transplantation
HSCT for Leukemia and Lymphoma
Recruiting1 awardPhase 2
Minneapolis, Minnesota
This trial is testing a new way to give an allogeneic HCT, which is a transplant of blood-forming cells from a donor. This new method uses a myeloablative preparative regimen, which is a way to kill cancer cells, followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen.
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.